Harrison.ai vs Paige
A side-by-side look at scores, pricing and features — with RECATOOLS' ASEAN-aware verdict for each.
Harrison.ai
Sydney radiology AI covering up to 124 chest X-ray findings
Visit
|
Paige
Cancer pathology AI behind the FDA-authorised Paige Prostate, now part...
Visit
|
|
|---|---|---|
| RECATOOLS Score | 8.2 / 10 | 8.2 / 10 |
| Capability | ||
| Value for money | ||
| Ease of use | ||
| ASEAN readiness | ||
| API quality | ||
| Pricing | Enterprise | Custom |
| Free tier | — | — |
| Paid from | Enterprise contracts quoted on request | Quoted per deployment; 30-day trial of the diagnostic suites on request |
| Has API | ✓ | ✓ |
| Open source | ✗ | ✗ |
| Free to use | ✗ | ✗ |
| Users | 3,400+ clinicians at 1,000+ sites across 40+ countries | In clinical use at hospitals and labs worldwide; training data spans 800+ labs across 45 countries |
| Founded | 2018 | 2017 |
| Maker | Dr. Aengus Tran (CEO) and Dimitry Tran (co-founder) | Tempus AI |
| Verdict | Harrison.ai offers unusually broad coverage in one product: up to 124 chest X-ray and 130 head CT findings with worklist prioritisation, deployed at more than 1,000 sites and in every public emergency department in Hong... |
Paige has the strongest regulatory record in AI pathology: a 2021 FDA De Novo authorisation for Paige Prostate, Breakthrough designations, and CE and UKCA marks across its suites. The evidence deserves careful reading, t... |
| Directory listing → | Full review → |
← Back to AI Directory
Comparisons cover up to 4 tools. Scores are RECATOOLS editorial assessments; verify current pricing on each vendor's site.